Author:
Tiwari Kalpana,Kumar Vikas,Kumar Ashish,Sharma Ambika,Vardhan Gyan,Dhamija Puneet
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Cancer-related inflammation;Mantovani A;Nature,2008
2. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience;Holstein SA;Drugs,2017
3. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. (2023). Accessed. May 16, 2023: https://www.science.org/doi/full/10.1126/science.1244851.
4. Identification of a primary target of thalidomide teratogenicity. (2023). Accessed. May 16, 2023: https://www.science.org/doi/full/10.1126/science.1177319.
5. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma;Quach H;Leukemia,2010